£13.9M
The financing round was backed by BGF, Parkwalk, and Meltwind to drive therapeutics discovery in autoimmune and other common diseases.
Enhanced Genomics
Biotechnology company pioneering 3D multi-omics to identify drug targets for common diseases.
£13.9MTotal raised
Enhanced Genomics operates a proprietary 3D multi-omics platform that maps genome-wide interactions to identify genetically validated drug targets for common diseases. The Cambridge-based biotechnology firm aims to accelerate pharmaceutical development and improve clinical success rates.
Categories
Team
DS
Dietrich Stephan
Chair